MedTrace Logo

A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT

NCT01639261 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-07-12

No results posted yet for this study

Summary

Improvement of quality of life in patients with BO and establishment of a new third line therapy

Conditions

  • Steroid-refractory Bronchiolitis Obliterans

Interventions

DRUG

Interferon gamma 1b

Initial dose: 50µg s.c. three times/week, without fever \>38,5 dose increase: 50µg/m² BSA three times/week

Sponsors & Collaborators

  • ClinAssess GmbH

    collaborator INDUSTRY

  • University Hospital Regensburg

    lead OTHER

Principal Investigators

  • Ernst Holler, Professor MD · University Hospital Regensburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-12-31
Completion
2014-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639261 on ClinicalTrials.gov